Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

NatWest and Halifax cut mortgage costs

View original at uk.finance.yahoo.com
NatWest and Halifax cut mortgage costs NatWest (NWG.L) and Halifax have both cut mortgage rates this week, while Nationwide (NBS.L) will allow buyers to borrow up to six times their income, fuelling expectations of a "booming market" in 2026…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The average rate for a two-year fixed mortgage came in at 4.49% this week

    80% confidence
  • The change to withdraw 60% LTV products was part of a reprice following the changes to swaps after the Bank of England held interest rates

    80% confidence
  • The average five-year fixed deal came in at 4.99%, a drop from the previous 5%

    80% confidence
  • With the right advice, borrowers can use that flexibility to move sooner and secure a deal that fits both the immediate need and the longer-term plan

    80% confidence
  • Nationwide extending six times income lending beyond first time buyers is a positive step, particularly as the first wave of Helping Hand customers starts to look at their next move

    80% confidence
  • It supports borrowers who are constrained by income multiples rather than the monthly cost, and shows how lenders are adapting to the reality of today's housing market

    80% confidence

Data points we hold from this source

Barclays · five year mortgage rate3.79 percent
Barclays · two year mortgage rate3.57 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com